ClinicalTrials.gg
RecruitingNCT07565428Updated Nov 13, 2026

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

A Phase 3 interventional study of Roluperidone and risperidone in Negative Symptoms of Schizophrenia, sponsored by Minerva Neurosciences. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Minerva Neurosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Planned enrollment
19th of 123
380 · median 100
Started
2026
the only one that year
Phase 3
34 of 127
2 open now
Registered
127th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 19th largest by planned enrollment of the 123 interventional ones that give a count, is the only one that started in 2026, is one of 34 in phase 3, and was the 127th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate of Roluperidone and antipsychotic medications.

03

Conditions studied

  • Negative Symptoms of Schizophrenia

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject and subject's legal representative, if applicable, provided prior to the initiation of any study related procedures, and the subject is judged by the investigator as being capable of understanding the study requirements.
  • Male or female, 18 to 55 years of age, inclusive, and (BMI) \</= 35.0 kg/m2 at Screening.
  • Meets the diagnostic criteria for schizophrenia as defined in the -Fifth Edition (DSM-5), as established by a full psychiatric interview in conjunction with the Mini International Neuropsychiatric Interview (MINI).
  • Has a caregiver or family member or health care personnel (as permitted by local regulations) who can provide information towards assessment and support the subject in terms of compliance with the protocol. The caregiver must have contact with the subject frequently and is not expected to change during the trial.
  • Documented diagnosis of schizophrenia for at least 1 year before screening into the trial.
  • Is stable in terms of both positive and negative symptoms of schizophrenia over the last 6 months according to his or her clinician and/or based on documentation in the clinical chart or medical records, and/or based on information from a caregiver or a family member when formal clinical documentation is not available. If information regarding symptoms stability is provided solely by a caregiver or a family member, it is essential that the caregiver or family member has been in regular contact with the participant during the 6 months prior to the Screening visit. The rationale for determining symptoms stability should be documented in the source records. Subjects with or without positive symptoms are allowed if these symptoms are stable for the last 6 months and the subjects do not meet exclusion criterion 2.
  • Is currently an outpatient and has not been hospitalized for the last 6 months for acute exacerbation or symptoms worsening.
  • Has had a stable living condition (residence) for the last 6 months.
  • Has not been hospitalized within 6 months before Screening. A subject hospitalized for any time period during the last 6 months for social reasons or currently hospitalized for reasons not related to their schizophrenia illness (e.g., has no support system in the community or needs to have eligibility for disability support periodically re-assessed) can be included only with sponsor/CRO's medical monitors approval and after considering the applicable local regulation requirements. The social reasons for admission or residing in a hospital must be documented in the source documents and the electronic case report form (eCRF).
  • Has a score of > 20 on the PANSS negative subscale score ([sum of N1+N2+N3+N4+N5+N6+N7]) at Screening (Visit 1) and Baseline (Visit 3) AND \< 4 points absolute difference between Visits 1 and 3.
  • Must discontinue any psychotropic medications by or at the beginning of the phase (Day -2). The rate of washout/discontinuation of psychotropic medications during the Screening period should be gradual in order to reduce the risk of psychotropic withdrawal symptoms but remains at the discretion of the investigator.
  • Has no history of violence against self or others.
  • Female subject, if not of , defined as a woman who is or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).
  • Female subject, if of childbearing potential, must test negative for pregnancy and must use 2 approved methods of highly effective .
  • Must be normal or ultrarapid metabolizer for cytochrome P450 (CYP) 2D6, defined as having an activity score (AS) of >/= 1.25 as determined by study-specific genotyping test before the first dose of study drug dose is administered.
  • Subject and the caregiver are considered by the investigator to be reliable and likely to cooperate with the assessment procedures.

Exclusion criteria

Exclusion Criteria:

  • Current major depressive disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, or intellectual disability (intellectual developmental disorder diagnosed by age 14), drugs or alcohol addiction.
  • PANSS item score of > 4 on any of the following items: P4 Excitement/Hyperactivity; P6 Suspiciousness/persecution; P7 Hostility; G8 Uncooperativeness; G14 Poor impulse control.
  • A Calgary Depression Scale for Schizophrenia (CDSS) total score > 6.
  • A score of >/= 2 on any 2 items of items 1, 2, or 3, or a score of >/= 3 on item 4 of the Barnes Akathisia Rating Scale (BARS). Patients who meet this exclusion criterion at the initial Screening visit may undergo a repeat BARS assessment at any time within the 4-week Screening period. Patients who no longer meet this exclusion criterion at the repeat assessment may be enrolled in the study, provided all other inclusion and exclusion criteria are met.
  • Subject's condition is due to direct physiological effects of a substance (e.g., a drug of abuse, or medication) or a general medical condition.
  • Current or recent history of serious suicidal behavior within the past 1 year.
  • History of substance use disorder within 3 months of the Screening visit (excluding caffeine and cigarette smoking).
  • Positive urine drug screen for any drug of abuse (cocaine, methadone, amphetamines, cannabinoids, opiates, benzodiazepines, and barbiturates), tricyclic antidepressants (TCA), and alcohol (except for prescription benzodiazepines).
  • Cannot be discontinued from psychotropics.
  • Received clozapine within 6 months of the Screening visit except when used for insomnia at doses \</= 100 mg per day.
  • Was treated with electroconvulsive therapy or transcranial magnetic stimulation in the last 12 months.
  • Is receiving treatment with long-acting or depot antipsychotic medication unless the drug has been discontinued for a full cycle drug (1 months, 3 months, 6 months depending on the drug formulation) to allow for sufficient before receiving the study drug.
  • History of significant renal disorder, including an \< 60 mL/min at the Screening visit.
  • History of significant other major or unstable neurological, neurosurgical (e.g., head trauma), metabolic, hepatic, hematological, pulmonary, cardiovascular, metabolic, gastrointestinal, urological disorder, or symptomatic orthostatic hypotension.
  • History of seizures (subjects with a history of a single childhood febrile seizure may be enrolled in this study).
  • abnormalities in hematology, blood chemistry (including or AST > 3 × the [ULN], total > 2 × ULN, or alkaline phosphatase > 1.5 × ULN), or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation.
  • Safety laboratory results from the Pretreatment Phase show one or more of the following: potassium \< 3.4 mmol/L, calcium \< 2.07 mmol/L, or magnesium \< 0.70 mmol/L.
  • Current systemic infection (e.g., , , [HIV], tuberculosis). A subject with positive Hepatitis B core antibody test and negative Hepatitis B Surface Antigen (HBsAg) may be included in the study if aminotransferase levels (alanine aminotransferase/ serum glutamate pyruvate transaminase [ALT/SGPT] and aspartate aminotransferase/ serum glutamic oxaloacetic transaminase [AST/SGOT]) do not exceed 2 × ULN.
  • Requires or may require concomitant treatment with any other medication likely to increase (e.g., paroxetine, fluoxetine, duloxetine, amiodarone).
  • Requires medication inhibiting CYP2D6.
  • Clinically significant abnormality that could be a safety issue in the study, including QT interval value corrected for heart rate using the Fridericia's formula (QTcF) > 430 msec for males and > 450 msec for females.
  • Familial or personal history of long QT syndrome or with another risk factor for Torsade de Pointes.
  • History of myocardial infarction based on medical history or ECG findings at Screening.
  • Syncope.
  • Woman of , or man, who is unwilling or unable to use accepted methods of .
  • Woman with a positive pregnancy test, is lactating, or is planning to become pregnant during the study.
  • Participated in another clinical study that was completed within 6 months prior to Screening or has previously participated in > 2 clinical studies with experimental medication within the past 2 years.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Placebo to Roluperidone

    Placebo administered as an oral dose daily from Day 1 to Week 12 (Phase A), then Roluperidone 64 mg administered as an oral dose daily from Week 12 +1 day to Week 64 (Phase B).

    Drug: Roluperidone · Drug: Placebo

  • Experimental
    Placebo to Antipsychotic

    Placebo administered as an oral dose daily from Day 1 to Week 12 (Phase A), then antipsychotic (risperidone 4 mg, aripiprazole 10 mg, or olanzapine 10 mg) administered as an oral dose daily from Week 12 +1 day to Week 64 (Phase B).

    Drug: risperidone · Drug: aripiprazole · Drug: olanzapine · Drug: Placebo

  • Experimental
    Roluperidone to Roluperidone

    Roluperidone 64 mg administered as an oral dose daily from Day 1 to Week 12 (Phase A), then Roluperidone 64 mg administered as an oral dose daily from Week 12 +1 day to Week 64 (Phase B).

    Drug: Roluperidone

  • Experimental
    Roluperidone to Antipsychotic

    Roluperidone 64 mg administered as an oral dose daily from Day 1 to Week 12 (Phase A), then antipsychotic (risperidone 4 mg, aripiprazole 10 mg, or olanzapine 10 mg) administered as an oral dose daily from Week 12 +1 day to Week 64 (Phase B).

    Drug: Roluperidone · Drug: risperidone · Drug: aripiprazole · Drug: olanzapine

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS)

    The Marder Negative Symptoms Factor Score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms. The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. Negative symptoms will be defined by PANSS negative subscore (N1+N2+N3+N4+N5+N6+N7). Higher scores indicate more severe symptoms.

    Time frame: Phase A: Screening, Baseline, Weeks 2, 4, 8, 12

Secondary outcomes

  1. Change from Baseline to Week 12 in the Personal and Social Performance (PSP) Total Score

    PSP scale=validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work \& study), personal \& social relationships, self-care, \& disturbing and aggressive behaviors. PSP is 100-item scale, divided in 10 similar intervals. Score based on first assessing patient's performance in 4 domains by assigning initial degree of severity (absent, mild, manifest, marked, severe, or very severe) to each domain. Second, a table with levels of score is used, setting correspondent decile (eg, 21-30), according to observed performance across the 4 domains. Third, within selected decile, final value is assigned (eg, within range 21-30, the performance corresponds to score 24). Resulting final value is single measurement from 0-100% of functioning. This single value is PSP total score. Lower scores 1-30=poor functioning; scores 31-60=varying degrees of disability; and scores 71-100=disability absence or only mild difficulties.

    Time frame: Phase A: Baseline and Weeks 4, 8, 12

  2. Change from Baseline to Week 12 in Clinical Global Impression - Severity of Illness Scale (CGI-S)

    The CGI-S is a clinician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function relative to the clinician's past experience with patients who have the same diagnosis and improvement with treatment. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating, according to: normal (not at all ill) = 1; borderline mentally ill = 2; mildly ill = 3; moderately ill = 4; markedly ill = 5; severely ill = 6; or extremely ill = 7.

    Time frame: Phase A: Screening, Baseline, and Weeks 2, 4, 8, 12

Other outcomes

  1. Safety Assessments

    Adverse Event assessment throughout the study from the time of informed consent form signature to End of Study.

    Time frame: Phase A: Screening through Week 12; Phase B: Week 12 +1 Day through Week 66

  2. Number of Subjects who Relapse over 12 Weeks of Double-blind Treatment (Phase A) and over 52 Weeks of Treatment (Phase B)

    The number and percentage of subjects who relapse in the roluperidone group versus the placebo group over 12 weeks of double-blind treatment in Phase A of the study and over 52 weeks of treatment in Phase B of the study will be summarized.

    Time frame: Phase A: Day 1 to Week 12; Phase B: Week 12 +1 Day to Week 64

07

Study locations

13 of 13 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 20 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 4, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedIs stable in terms of both positive and negative symptoms of schizophrenia over the last 6 months according to his or her clinician and/or based on documentation in the clinical chart or medical records, and/or based on information from a professional caregiver (where permitted by local regulations)or a family member when formal clinicianclinical documentation is not available. If information regarding symptoms stability is provided solely by a caregiver or a family member, it is essential that the caregiver or family member has been in regular contact with the participant during the 6 months prior to the Screening visit. The rationale for determining symptoms stability should be documented in the source records. Subjects with or without positive symptoms are allowed if these symptoms are stable for the last 6 months and the subjects do not meet exclusion criterion 2.
Exclusion criteria
  • EditedA score of >/= 2 on any 2 items of items 1, 2, or 3, or a score of >/= 3 on item 4 of the Barnes Akathisia Rating Scale (BARS). Patients who meet this exclusion criterion at the initial Screening visit may undergo a repeat BARS assessment at any time within the 4-week Screening period. Patients who no longer meet this exclusion criterion at the repeat assessment may be enrolled in the study, provided all other inclusion and exclusion criteria are met.
Nov 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange from Baseline to Week 12 in Clinical Global Impression - Severity of Illness Scale (CGI-S) ScaleTime frame: Phase A: Screening, Baseline, and Weeks 2, 4, 8, 12
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedIs stable in terms of both positive and negative symptoms of schizophrenia over the last 6 months according to his or her clinician and/or based on documentation in the clinical chart or medical records, and/or based on information from a professional caregiver (where permitted by local regulations)or a family member when formal clinicianclinical documentation is not available. If information regarding symptoms stability is provided solely by a caregiver or a family member, it is essential that the caregiver or family member has been in regular contact with the participant during the 6 months prior to the Screening visit. The rationale for determining symptoms stability should be documented in the source records. Subjects with or without positive symptoms are allowed if these symptoms are stable for the last 6 months and the subjects do not meet exclusion criterion 2.
    Exclusion criteria
    • EditedA score of >/= 2 on any 2 items of items 1, 2, or 3, or a score of >/= 3 on item 4 of the Barnes Akathisia Rating Scale (BARS). Patients who meet this exclusion criterion at the initial Screening visit may undergo a repeat BARS assessment at any time within the 4-week Screening period. Patients who no longer meet this exclusion criterion at the repeat assessment may be enrolled in the study, provided all other inclusion and exclusion criteria are met.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from Baseline to Week 12 in Clinical Global Impression - Severity of Illness Scale (CGI-S) ScaleTime frame: Phase A: Screening, Baseline, and Weeks 2, 4, 8, 12
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07565428
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Apr 23, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Chief Operating Officer
Contact
info@minervaneurosciences.com
617-600-7373

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roluperidone · Risperidone · Aripiprazole · Olanzapine

Start the discussion